<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085185</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI110A101</org_study_id>
    <nct_id>NCT04085185</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors</brief_title>
  <official_title>A Phase 1a, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability,
      pharmacokinetics and efficacy of IBI110 in subjects with advanced malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with AEs and SAEs</measure>
    <time_frame>up to 2 years after enrollment</time_frame>
    <description>To evaluate the safety and tolerability of IBI110 alone or in combination with Sintilimab [Adverse events (AEs), Serious Adverse Events (SAEs) ]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>From Baseline to the end of Cycle 1</time_frame>
    <description>To evaluate the safety and tolerability of IBI110 alone or in combination with Sintilimab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC</measure>
    <time_frame>up to 2 years after enrollment</time_frame>
    <description>The area under the curve (AUC) of serum concentration of the drug after the administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>up to 2 years after enrollment</time_frame>
    <description>Maximum concentration (Cmax) of the drug after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Percentage of ADA positive subjects</measure>
    <time_frame>up to 2 years after enrollment</time_frame>
    <description>Immunogenicity: Number of Anti-Drug Antibodies (ADA) positive subjects will be counted and percentage of ADA positive subjects will be calculated to evaluate immunogenicity of IBI110.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of IBI110 (Objective Response Rate)</measure>
    <time_frame>up to 2 years after enrollment</time_frame>
    <description>Objective Response Rate (ORR) is the percentage of Complete Response (CR) plus partial response (PR) assessed by RECIST v1.1 criteria for solid tumors and Lugano2014 criteria for lymphoma.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>Phase Ia Dose-Escalation Stage:IBI110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with escalating doses of IBI110 to determine the MTD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ia Expansion Stage:IBI110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in different cancer types.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Dose-Escalation Stage:IBI110+ Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with escalating doses of IBI110 in combination with a fixed dose of Sintilimab to determine the MTD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Expansion Stage:IBI110+ Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in combination with Sintilimab in different cancer types.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI110</intervention_name>
    <description>Several dose levels will be evaluated for IBI110 administered as a single agent and in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI110 may receive combination treatment with IBI110 plus Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.</description>
    <arm_group_label>Phase Ia Dose-Escalation Stage:IBI110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI110</intervention_name>
    <description>IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.</description>
    <arm_group_label>Phase Ia Expansion Stage:IBI110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI110+ Sintilimab</intervention_name>
    <description>IBI110: Several dose levels will be evaluated for IBI110 in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit.</description>
    <arm_group_label>Phase Ib Dose-Escalation Stage:IBI110+ Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI110+ Sintilimab</intervention_name>
    <description>IBI110: IBI110 in combination with Sintilimab will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit.</description>
    <arm_group_label>Phase Ib Expansion Stage:IBI110+ Sintilimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to understand and willing to sign the ICF.

          2. Adults 18 years of age or older.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          4. Life expectancy at least 12 weeks.

          5. Adequate organ and bone marrow function.

          6. Histologically/cytologically confirmed, locally advanced unresectable or metastatic
             solid tumors and lymphomas that are refractory to standard therapy, or for which no
             standard therapy exists.

          7. Measurable disease according to RECIST Version 1.1 in solid tumor.

          8. Subjects (women of child-bearing potential and males) must be willing to use viable
             contraception method that is deemed effective by the investigator throughout the
             treatment period and for at least three months following the last dose of study drug.
             Postmenopausal women must have been amenorrhoeic for at least 12 months to be
             considered of non-childbearing potential.

        Exclusion Criteria:

          1. Previous exposure to any anti-lag-3 antibody.

          2. Participate in another interventional clinical study, except for the observational
             (non-interventional) clinical study or the survival follow-up phase of the
             interventional study.

          3. Any investigational drugs received within 4 weeks prior to the first study treatment.

          4. Receive the last dose of anti-tumor therapy within 4 weeks before the first dose of
             study therapy.

          5. Immunosuppressive drugs were used within 4 weeks prior to the first administration of
             the study drug.

          6. Medication requiring long-term systemic hormones or any other immunosuppression
             therapy.

          7. Major surgical procedures (craniotomy, thoracotomy, or laparotomy) or unhealed wounds,
             ulcers, or fractures were performed within 4 weeks prior to the first dose of study
             therapy.

          8. There were unrecovered toxicity (excluding hair loss or fatigue) according to NCI
             CTCAE v5.0 induced by previous antitumor therapy (24 weeks before the first dose of
             study), and there were unrecovered immune-related adverse events (irAE) associated
             with immunotherapy.

          9. Previous immunotherapy, such as anti-PD-1 / anti-PD-L1 antibody or anti-CTLA4
             antibody, was discontinued due to the presence of &gt; grade 3 irAE.

         10. Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases,
             or leptomeningeal disease.

         11. History of autoimmune disease , present active autoimmune disease or inflammatory
             diseases

         12. Present or history of pulmonary diseases such as interstitial pneumonia,
             pneumoconiosis, drug-related pneumonia, pulmonary fibrosis, active pulmonary
             infection, severely impaired pulmonary function.

         13. Positive human immunodeficiency virus (HIV) test.

         14. Active hepatitis B or C, or tuberculosis.

         15. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell
             transplantation. 16. History of gastrointestinal perforation and/or fistula at 6
             months prior to study inclusion.

        17.Hydrothorax, ascites, and pericardial effusion with clinical symptoms requiring
        drainage.

        18.Known history of hypersensitivity to any components of the IBI110 or Sintilimab.

        19.Uncontrolled complications of disease.

        20.Other acute or chronic illness, mental illness, or abnormal laboratory test values that
        may increase the risk of study participation or administration of study drugs, or interfere
        with the interpretation of study results.

        21.History of other primary malignancies. 22. Pregnant or nursing females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qian Qu, Bachelor</last_name>
    <phone>86-18501735865</phone>
    <email>qian.wu@innoventbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caicun Zhou, M.D</last_name>
    <phone>+86 21 65115006</phone>
    <email>caicunzhoudr@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caicun Zhou</last_name>
      <phone>021-65115006</phone>
      <email>caicunzhoudr@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

